Achillion preclinical data

In vitro, ACH-3102 provided higher potency than daclatasvir from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) against HCV genotype 1a infection and comparable potency against HCV genotype 1b i...